SB 1188 automatically aligns Arizona's controlled substance scheduling with federal classifications for FDA-approved medications (excluding Schedule I drugs), meaning Arizona will adopt the same schedules as the U.S. Drug Enforcement Administration without requiring separate state action. This allows healthcare providers in Arizona to prescribe these medications as permitted under federal law, eliminating the need for the state pharmacy board to reclassify them. The bill directly affects the Arizona State Board of Pharmacy and medical professionals who prescribe or dispense controlled substances by simplifying scheduling requirements. It applies only to drugs approved by the FDA and scheduled by the federal government (other than Schedule I), ensuring consistency with federal regulations.
SB 1630 establishes a new Arizona Medicaid program providing home and community-based services for adults with serious mental illness, replacing institutional care when possible. It sets eligibility based on clinical criteria (like recent hospitalizations, medication complexity, or safety risks) and income limits (300% of federal SSI), with options for a qualified income trust to meet financial requirements. Covered services include personal care, medication management, supervised community living, adult day health, and nonemergency transportation. The program requires federal approval by 2027 and aims to support individuals in community settings while avoiding psychiatric hospital or residential facility placement.
SB 1814 establishes a temporary study committee to examine Arizona's substance use disorder treatment system. The committee, composed of legislators, health officials, clinicians, and individuals with lived experience, will study treatment availability, gaps in care, regulatory loopholes, and workforce needs. It must report by December 31, 2027, with recommendations for evidence-based standards, oversight reforms, and funding strategies. The committee expires on June 30, 2028, and does not enact new laws.
SB 1214 restricts Arizona physicians from using stem cells or birth tissue derived from aborted fetuses or embryos for therapy. It allows non-FDA-approved stem cell or birth tissue therapies only for orthopedics, wound care, or pain management, provided the cells come from FDA-registered or certified facilities (like blood banks or tissue banks) and meet specific safety and viability standards. The bill requires physicians to disclose in advertising and obtain detailed informed consent stating the therapy isn't FDA-approved, and mandates facilities to provide full certification details to physicians. These provisions directly affect medical providers, clinics, and tissue suppliers offering such therapies in Arizona.
SB 1165 prohibits Arizona health insurance plans (including hospital service corporations and health care service organizations) from charging cost-sharing fees (like deductibles or copays) for diagnostic and supplemental breast exams starting January 1, 2027. Diagnostic exams cover evaluations of abnormalities found during screenings or other tests, while supplemental exams are risk-based screenings for individuals with dense breasts, family history, or other factors. The bill requires insurers to cover these exams without cost-sharing even before a high-deductible plan’s deductible is met, aligning with National Comprehensive Cancer Network guidelines. It directly affects insurance providers and beneficiaries seeking these specific breast cancer screening services.
SB 1235 establishes Arizona's participation in the Emergency Medical Services (EMS) Licensure Interstate Compact. It allows licensed EMTs, AEMTs, and paramedics from Arizona (the "home state") to practice in other participating states ("remote states") without obtaining new licenses, provided Arizona meets specific standards like requiring the national NREMT exam for initial licensure and sharing adverse actions. The compact requires member states to verify competency, share license-related disciplinary information, and maintain systems for cross-state recognition. This directly affects Arizona-licensed EMS personnel seeking to work temporarily in other member states and state EMS authorities managing licensure verification.
SB 1145 requires the State Board of Psychologist Examiners to include two behavior analysts in professional practice as voting members (who must also serve on a dedicated committee for behavior analysts). The bill mandates that the board must seek and consider the committee's recommendations on all licensing, regulatory, and practice-related decisions affecting behavior analysts before taking action. This directly impacts licensed behavior analysts in Arizona by ensuring their professional input shapes regulatory rules and standards. The change formalizes existing advisory roles into a structured requirement under Arizona law.
Arizona's HB 2248, titled the "Arizona Medical Freedom Act," bans businesses, schools, and government entities from requiring medical interventions (like vaccines or treatments) as a condition for services, employment, school attendance, or access to facilities. It specifically prohibits: denying services or entry based on vaccination status, requiring interventions for employment (except for foreign travel requirements), or offering different pay based on whether someone has received a medical intervention. The law includes exceptions for standard workplace safety equipment under industry standards (but excludes pandemic-era mandates like mask requirements) and does not apply to schools operating under parental rights laws. Violations can be enforced by the attorney general, who may seek court orders and recover legal fees.
SB 1243 updates Arizona's rules for releasing patients from court-ordered mental health treatment. It requires medical directors of treatment agencies to notify guardians, courts, and certain relatives or victims at least 10 days before releasing patients who no longer need inpatient care. For patients treated as dangers to others (under Section 13-4517), the bill mandates additional notice to prosecutors and courts at least 5 days prior to release. This affects patients in court-ordered treatment, their guardians, mental health agencies, and the courts overseeing these cases.
SB 1095 prohibits health professionals in Arizona from providing gender transition procedures, irreversible gender reassignment surgery, or referrals for such procedures to individuals under 18 years old. The bill allows exceptions for medical conditions like disorders of sex development (e.g., XX virilization or XY undervirilization) or treatments for infections, injuries, or life-threatening conditions. It also bans the use of public funds for gender transition procedures for minors in state-run facilities or by state-employed health professionals. The law establishes disciplinary action for violations and allows individuals to seek legal remedies for noncompliance.
